Key facts
- Notable investors include Scale Up Partners.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Clichembio
- ·The full record, as it builds
Funding rounds
No funding rounds for Clichembio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Clichembio
Developer of albumin theranostics nano platform designed for drug development. The company offers drugs for anti-inflammatory and anticancer diagnostic combination therapy, and nuclear medicine research, used in clinical settings through proof-of-concept in efficacy evaluation, enabling the healthcare industry to improve national health and quality of life.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2022
- Website
- clichembio.com/
- Ownership
- Privately Held (backing)
Clichembio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Clichembio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Clichembio in its N-PORT filings yet. We sweep new filings monthly.